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ABSTRACT
Repulsive guidance molecules (RGMs) are co-receptors of bone morphogenetic 
proteins (BMPs) and programmed death ligand 2 (PD-L2), and might be involved 
in lung and other cancers. We evaluated repulsive guidance molecule B (RGMB) 
expression in 165 non-small cell lung cancer (NSCLC) tumors and 22 normal lung 
tissue samples, and validated the results in an independent series of 131 samples. 
RGMB was downregulated in NSCLC (P ≤ 0.001), possibly through promoter 
hypermethylation. Reduced RGMB expression was observed in advanced-stage tumors 
(P = 0.017) and in tumors with vascular invasion (P < 0.01), and was significantly 
associated with poor overall survival (39 vs. 62 months, P < 0.001) and with disease-
associated patient mortality (P = 0.015). RGMB knockdown promoted cell adhesion, 
invasion and migration, in both NSCLC cell lines and an in vivo mouse model, which 
enhanced metastatic potential. Conversely, RGMB overexpression and secretion 
suppressed cancer progression. The tumor-suppressing effect of RGMB was exerted 
through inhibition of the Smad1/5/8 pathway. Our results demonstrate that RGMB is 
an important inhibitor of NSCLC metastasis and that low RGMB expression is a novel 
predictor or a poor prognosis.
INTRODUCTION
Lung cancer is one of the most commonly diagnosed 
malignancies and accounted for approximately 13% of the 
total cancer diagnoses in 2012. It is the leading cause of 
cancer death in males and second leading cause in females 
worldwide [1]. Non-small cell lung cancer (NSCLC) 
accounts for more than 85% of all lung cancer cases 
and includes adenocarcinoma, large-cell carcinoma, and 
squamous cell carcinoma [2]. Despite advances in early 
detection and improvements in treatment, the long-term 
survival rates for NSCLC remain poor as a consequence 
of distant metastasis.
Repulsive guidance molecules (RGMs) are 
glycosylphosphatidylinisotol (GPI)-linked membrane 
proteins consisting of three family members (RGMA, 
RGMB, and RGMC). Repulsive guidance molecule B 
(RGMB), also known as Dragon (‘turned on in DRG’), 
was the first RGM family member identified. RGMB, 
which is transcriptionally regulated by DRG11 [3], 
is a myelin-derived inhibitor of axon growth in the 
central nervous system [4] and a co-receptor for bone 
morphogenetic proteins (BMPs) [5]. 
BMPs are involved in the development and 
progression of various malignancies including breast, 
prostate, lung, and colorectal cancers, as well as melanoma 
and osteosarcoma [6, 7]. As a group of osteogenic 
factors, BMPs play key roles in the development of bone 
metastases [8–12] by coordinating bone formation, bone 
disruption, angiogenesis, and tumor growth through 
SMAD-dependent and -independent pathways [7]. RGMs 
may be involved in cancer development and progression 
by participating in the BMP signaling pathway. RGMB 
was also reported to be a receptor for PD-L2, a known 
ligand of PD-1. The PD-1/PD-L1 pathway provides a 
particularly promising strategy for cancer immunotherapy 
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[13, 14]. Our previous study highlighted the aberrant 
expression profile of RGMs in breast cancer and indicated 
potential links between RGMs and patient prognosis [15]. 
However, the role of RGMB in lung cancer metastasis is 
unclear. 
In the present study, we demonstrate that reduced 
RGMB gene expression is significantly associated with 
progression, metastasis, and poor prognosis in NSCLC. 
Suppression of RGMB promoted metastasis, thereby 
providing mechanistic insight into the role of RGMB in 
lung cancer development. 
RESULTS
RGMB is downregulated in NSCLC tumors 
A statistically significant decrease in RGMB 
transcript expression (Figure 1B) was observed in 
NSCLC tumors compared to normal lung tissues. 
Immunohistochemical (IHC) staining of RGMB showed 
a cytoplasmic distribution in alveolar epithelial cells, 
bronchial epithelial cells, and parts of the lung cancer 
cells in human lung tissue sections (Figure 1A). In 
comparison with other NSCLC subtypes, the RGMB 
level was significantly higher in adenocarcinomas 
(P ≤ 0.001; Figure 1C). There were no significant 
differences in RGMB expression with respect to the age, 
sex, and smoking status of the patients.
Reduced RGMB expression is associated with 
disease progression and poor prognosis
Lower RGMB transcript levels were observed in 
more advanced-stage tumors and tumors with vascular 
invasion (Figure 1D). Early-stage tumors had higher 
RGMB expression compared to more advanced-stage 
tumors (P = 0.017, Figure 1E). RGMB protein levels were 
reduced in advanced-stage tumors compared to early-stage 
tumors and normal tissues as assessed by IHC staining 
(Figure 1A). 
The association between disease progression/
prognosis and RGMB expression was initially examined 
in 165 NSCLC patients. Survival rates were compared 
between patient groups that were defined using the 
median RGMB expression level (3.12 copies) as the cut-
off threshold. Patients with tumors expressing higher 
RGMB levels had longer overall survival (OS, median 
= 62 months; 95% confidence interval [CI], 58.9–66.1 
months) compared to patients with tumors expressing 
lower RGMB levels (median = 39 months; 95% CI, 
27.0–51.0 months) (Figure 1G; P < 0.001; Table 1). 
In addition, RGMB expression remained significantly 
correlated with OS after adjustments for age, sex, 
smoking status, and clinical stage, suggesting that 
RGMB is an independent prognostic predictor (Table 2). 
The association between RGMB expression and 
patient prognosis was then validated in a cohort of 131 
NSCLC patients who were recruited between 2009 and 
2010. Kaplan-Meier survival curves and log-rank tests 
showed a trend towards improved OS in patients with 
higher RGMB levels, though the improvement was not 
statistically significant.
Analysis of pooled data from the two cohorts 
using an inverse variance meta-analysis revealed a 
significant association between RGMB transcript levels 
and prognosis, which was independent of clinical 
stage (Hazard ratio [HR], 0.61; 95% CI, 0.5–0.74; 
P = 8.11 × 10−7) (Table 2). Because clinical stage is also a 
significant factor for prognosis, we further demonstrated 
the independent prognostic role of RGMB in early- and 
late-stage sub-groups of a cohort of lung cancer patients 
(Table 3). RGMB expression was found to be significantly 
associated with lung cancer-associated mortality 
(Figure 1F; P = 0.015). 
RGMB suppresses adhesion, invasion, and 
migration of lung cancer cells in vitro
The association between RGMB expression and 
NSCLC prognosis prompted us to investigate whether 
manipulation of RGMB gene expression would alter 
the malignant phenotype. We first evaluated RGMB 
expression in lung cancer cell lines (Figure 2A). RGMB 
expression was observed in PC-9, A0907, H1395, H1299, 
and A-549 cell lines and was weakly expressed in H520, 
HCC827 and Am1010 cell lines. Therefore, RGMB was 
knocked down or overexpressed in both A-549 and H1299 
cells (Figure 2B, Figure S1). 
Although alteration of RGMB expression did not impact 
the proliferation of NSCLC cells (Figure S2A, S2B and S2C), 
cell adhesion and invasion were significantly enhanced 
or suppressed by RGMB knockdown or overexpression, 
respectively (Figure S3, Figure 2C and 2D). Electric cell 
substrate impedance sensing (ECIS) and wounding assays 
showed that the ability of the lung cancer cells to attach 
(Figure 2E) and migrate (Figure 2F, 2G and Figure S3) 
was enhanced by RGMB knockdown. An Fc fusion protein 
variant of RGMB that is released from cells in a soluble form 
was reported previously [3]. In the present study, invasion 
and migration assays showed that co-culture of RGMB-
overexpressing cells (using a transwell system) with lung 
cancer cells resulted in reduced invasion and migration 
of the lung cancer cells. It is possible that this effect was 
mediated by the RGMB Fc protein (without the GPI anchor) 
(Figure 2H and 2I).
RGMB influences the metastatic dissemination 
of lung cancer cells in a murine tumor model
To examine the role of RGMB in tumorigenicity 
in vivo, we established xenograft models by 
subcutaneously injecting A-549 RGMB-knockdown 
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cells into mice. Metastatic dissemination of the 
tumor cells to the lungs was observed by two-photon 
microscopy. No differences were observed in primary 
tumor growth between control and RGMB-knockdown 
A-549 subcutaneous tumors (Figure S2 D). However, an 
increased number of GFP-labeled RGMB-knockdown 
cells migrated to the lung compared to the A-549 empty 
vector controls (Figure. 3A). Moreover, the metastatic 
lung tumor burden significantly differed between the 
vector and RGMB-knockdown groups 6 weeks after 
Figure 1: RGMB expression and association with lung cancer progression. (A) Representative IHC images show a high level 
of RGMB expression in normal lung tissues (left, N), weak expression of RGMB in stage I tumors (middle), and the absence of RGMB 
expression in stage IV tumors (right) (scale bar = 100 µm). (B–E) RGMB transcription levels in (B) lung cancer [T, median: 1,217.815, 
interquartile range (IQR) 9,073.67, n = 296] and background tissues (N, median: 83,114.17, IQR: 259,640.2, n = 22, P ≤ 0.001), (C) in 
adenocarcinoma (ADC, median: 1,462.276, IQR: 10,349.5, n = 270), squamous cell carcinoma (SCC, median: 725.313, IQR: 10,651.07, 
n = 17) and other histological types (median: 48.912, IQR: 81.169, n = 9, P ≤ 0.001), (D) in patients with vascular invasion (median: 
420.478, IQR: 7651.594, n = 8) and without vascular invasion (median: 1,319.333, IQR: 10814.95, n = 292, P ≤ 0.1), (E) in early-
stage patients (median: 2,358.109, IQR: 109860, n = 261) and late-stage patients (median: 1,025.724, IQR: 9814.407, n = 33, 
P = 0.017). (F) Patients with better clinical outcomes have higher RGMB expression levels (median: 3,153.453, IQR: 17,853.13, 
n = 197) compared to those with poor outcomes (median: 710.577, IQR: 6,350.661, n = 85, P = 0.015). (G) Kaplan-Meier survival 
curves show the overall prognosis of patients with high RGMB expression (median: 62 months, 95% CI 58–67, P < 0.001) and low 
RGMB levels (median: 39 months, 95% CI 27–51) based on log-rank tests.
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tumor cell inoculation (Figure. 3B). More cancer cells 
were present in the circulation and at distant metastatic 
sites such as the liver, bone marrow, and spleen following 
RGMB knockdown as detected via fluorescence activated 
cell sorting (FACS) (Figure 3C and 3D; Table 4).
RGMB signaling model 
Based on previous studies and our findings, the model 
for RGMB signaling we propose is described in Figure 4. 
There are two signaling pathways by which BMPs activate 
intracellular signaling molecules: the Smad-dependent 
and Smad-independent pathways [16]. Smad1/5/8 and 
Smad2/3 are responsible for the Smad-dependent pathway. 
The Smad-independent (MAPK) pathway consists of a 
chain of activation in which MAPK (as JNK, ERK1/2) 
is activated following sequential activation of MAP4K/
MAP3K/MAP2K [17]. Two different types of serine-
threonine kinase transmembrane BMP receptors (Types I 
and II) are indispensable for both pathways upon activation 
by BMPs [18]. An increase in phosphorylated Smad-1/5/8 
levels was observed in RGMB knockdown cells (Figure 
5A). In addition, knockdown of Smad1 eliminated RGMB 
knockdown-enhanced cell migration (Figure. S4). No 
changes were observed in activation of ERK and JNK in 
RGMB knockdown cells (Figure 5A). 
Table 1: Log-rank test on OS for RGMB
Group Patients(No)
Median 
(Months) 95% CI P
Discovery set
Low RGMB 80 39 27.0–51.0 4.07E-5
High RGMB 77 62 58.9–66.1
Validation set
Low RGMB 66 42 39.7–45.1 0.072
High RGMB 58 59 52.4–65.4
Table 2: Cox proportional hazard model
Discovery Replication Fixed effect meta analysis
Factor HR 95% CI p-value HR 95% CI P-value HR 95% CI P-value Phet
RGMB 0.57 0.458–0.710 4.85E–07 0.62 0.381–1.007 0.05 0.61 0.5–0.74 8.11E–07 0.19
Age 1.95 1.150–3.317 0.13 1.30 0.535–3.169 0.56 1.69 1.07–2.66 0.02 0.29
Gender 0.94 0.559–1.585 0.82 0.90 0.370–2.2.5 0.82 0.94 0.6–1.49 0.81 0.98
Smoking status 0.94 0.615–1.445 0.79 0.62 0.234–1.639 0.34 0.92 0.62–1.36 0.68 0.78
Clinical  
stage 1.61 1.269–2.041 8.87E–05 1.92 1.216–3.045 0.01 1.55 1.25–1.91 5.38E–05 0.47
Table 3: Subgroup analysis of Cox proportional hazard model
Subgroup Factor HR LCI HCI p-value
Early stage 
(I–IIIA)
RGMB 0.2872 1.1794 1.6489 1.04E–05
age 1.6655 2.6435 17.3451 6.33E–02
gender 0.8284 1.6111 4.2156 5.04E–01
smoking 0.7877 1.6454 3.4766 3.08E–01
Late stage 
(IIIB–IV)
RGMB 0.2736 1.0863 2.4699 3.36E–02
age 1.6669 1.7580 137.7135 3.55E–01
gender 1.0159 1.4215 18.8099 9.77E–01
smoking 1.5842 2.3281 19.4845 1.51E–01
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Potential mechanism of RGMB downregulation 
in lung cancer
To investigate the potential mechanisms underlying 
downregulation of RGMB in lung cancer, the methylation 
of the RGMB gene was screened in four paired human 
samples. In total, 83 CpG positions derived from 
67 CpG units in RGMB were analyzed. Of these positions, 
successful measurements for all four samples were 
obtained for 72% of the CpG units. We found that most 
of the CpG units in three tumor samples (T1, T2, and T3) 
were methylated to a very low extent, with an average 
methylation level of < 20%. This was similar to the level 
of methylation in the normal samples. Only one sample 
(T4) had four CpG units that displayed methylation 
levels > 50%, which differed from the normal tissue (low 
methylation level) (Figure 5B). 
We performed real-time quantitative PCR (qPCR) 
assays to further investigate the association between CpG unit 
methylation and RGMB expression. The tumor (T4) that had 
a higher methylation level compared to that of the normal 
adjacent tissue (N4) had significantly decreased RGMB 
expression (Figure 5C). However, the other three tumors 
(T1, T2, and T3) did not show obvious changes in methylation 
status. These results suggest that the methylation of CpG units 
in the RGMB promoter region is only one of the mechanisms 
by which RGMB is downregulated in some lung cancer tumors.
DISCUSSION
The present study revealed that RGMB is 
downregulated in lung cancer and that downregulation 
of RGMB is correlated with poor prognosis and shorter 
OS. Our results also suggest that hypermethylation of 
Figure 2: Manipulation of RGMB alters the malignant behavior of lung cancer cells in vitro. (A) Screening of RGMB in 
lung cancer cell lines. (B) Western blot showing that RGMB expression is significantly repressed or increased in A-549 cells. RGMB can 
be detected in A-549 cells at a molecular weight of approximately 45 kD, with slightly weaker staining of another band observed at a lower 
molecular weight. The image is representative of three independent experiments. (C–F) RGMB overexpression inhibits cell adhesion (C) 
and invasion (D) in A-549 cells, *P < 0.05. ECIS assay showing that the repression of RGMB expression enhances the ability of lung cancer 
cells to adhere (E) and migrate (F). (G) Wound healing assay showing the enhanced migration ability of RGMB-knockdown A-549 cells. 
A comparison of the migration distance at each time point is shown in the graph. (H–I) Co-culture of RGMB-overexpressing cells with 
A-549 or H1299 cells inhibits the ability of the cancer cells to invade (H) and migrate (I) compared to co-culture with vector control cells.
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the RGMB promoter is one mechanism underlying the 
downregulation of RGMB in lung cancer. We performed 
an analysis of 448 lung adenocarcinomas (LUAD) and 
364 lung squamous cell carcinoma (LUSC) methylation 
normalized RNAseq2 datasets, which were downloaded 
from The Cancer Genome Atlas Research Network 
(http://cancergenome.nih.gov/). The methylation and log-
normalized RNAseq2 data demonstrated an inversely 
proportional relationship in both the LUAD and LUSC 
datasets (Figure S5). These results indicate that RGMB 
expression is downregulated as a result of the degree 
of methylation, which is in line with our observations. 
Furthermore, there is evidence that RGMB gene 
expression could be up-regulated by hepatocyte growth 
factor in HECV endothelial cells [19]. RGMB is expressed 
by different cell types and may contribute to tumor growth 
Figure 3: RGMB gene manipulation alters lung cancer metastasis in vivo. (A) Repression of RGMB increases migration 
of tumor cells into the lung. GFP-labeled tumor cells observed with a two-photon microscope are shown (scale bar = 200 µm). (B) 
Representative image showing metastatic tumor loci that formed in the lungs of mice injected with RGMB-knockdown or vector control 
A-549 cells. The bar graph shows counting of the tumor loci size using Image J in three fields per slide. (C) Metastatic lung cancer cells 
detected by flow cytometry. (D) Detection of metastatic RGMB-knockdown cells in different organs compared to control cells.
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Table 4. The in vivo metastasis of cancer cells
Cell line/metastasis site
Cancer cell rate (percentage, mean ± SD)
Blood Spleen Bone marrow Liver
control 1.18 ± 0.15 3.02 ± 1.46 0.29 ± 0.12 3.93 ± 0.05
RGMB knockdown 3.38 ± 0.88 11.66 ± 13.87 2.56 ± 0.20 15.14 ± 4.80
P value 0.15 0.02 0.04 0.02
Figure 4: RGMB model. Knockdown of RGMs facilitates BMP signaling through the Smad1/5/8 pathway and partly through Smad2/3. 
The MAPK-JNK pathway is inhibited thereby mediating the expression of BMP downstream genes. FAK/paxillin is induced by BMP 
through Smad1/5/8 and TGF-ß through Smad2/3. It also interacts with components of the ERK1/2 pathway [26]. Expression of focal 
adhesion proteins is primarily stimulated by activation of Smad1/5/8 and partially by Smad2/3 in the absence of RGMB, which leads to 
increased cell adhesion in breast cancer. Snai1 can be induced by TGF-ß through Smad2/3 [27]. Regulation of Snai1 is also associated 
with Smad1/5/8 activation after RGMB knockdown, which induces EMT. ID-1 is upregulated or downregulated by TGF-ß via Smad2/3, 
depending on the phase [28, 29], and it can also be activated by BMPs through Smad1/5/8 and the PI3K/Akt pathway [30–32]. Knockdown 
of RGMs in prostate cancer cells has been shown to result in upregulation of ID-1 primarily through Smad2/3, which may promote cell 
proliferation [33], migration [34], and adhesion [32]. Knockdown of RGMB suppressed expression and activation of caspase-3 (executes 
the cell apoptotic program) and reduced c-Myc expression, which may also be involved in the regulation of cell death. Binding of RGMs to 
neogenin may trigger different pathways that mediate neuronal growth, differentiation, and iron metabolism [35–38]. RGMB binds PD-L2, 
which promotes respiratory immunity independent of another PD-L2 receptor, PD-1, which inhibits antitumor immunity [14].
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and progression. Additionally, it may be regulated by a 
variety of cytokines/pathways that are yet to be fully 
investigated. 
In line with the observations from the NSCLC 
tumors, our in vitro and in vivo data have shown that 
RGMB can inhibit NSCLC cell metastasis. Further 
investigations have revealed that the inhibitory effect 
of RGMB in lung cancer is occurs primarily through 
suppression of the Smad-1/5/8-dependent pathway. The 
activation of Smad-1/5/8 observed in RGMB knockdown 
cells could have resulted in transcriptional regulation of 
BMP-responsive genes [20, 21], and enhanced invasion 
and migration of cancer cells. Blocking Smad1 in 
RGMB-knockdown A-549 cells diminishes the RGMB 
knockdown-enhanced migration of these cells suggesting 
that RGMB can inhibit the metastatic potential of lung 
Figure 5: The signaling pathway and potential mechanism of RGMB downregulation in lung cancer. (A) Western blot 
results showing that RGMB knockdown induces Smad-1 phosphorylation (P-Smad-1) but has no stimulatory effect on the expression 
(ERK, JNK) or phosphorylation (P-ERK, P-JNK) of components of the Smad-independent pathway. (B) Methylation levels of RGMB CpG 
units in N4 and T4 samples. (C) RGMB expression in tumor and normal samples, as determined by qPCR assays.
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cancer cells through suppression of the Smad-1/5/8 
pathway.
In summary, our results suggest that the RGMB is 
a prognostic biomarker in NSCLC and has therapeutic 
potential because it can prevent metastasis.
MATERIALS AND METHODS
NSCLC tumor samples
All samples were collected during surgery at 
the First Affiliated Hospital of Guangzhou Medical 
University. In total, 165 tumor samples and 22 normal 
lung tissue samples were obtained from patients who 
were enrolled in the study between April 2007 and June 
2009. An additional 131 tumor samples were collected 
from patients between June 2009 and June 2010. The 
tissues obtained during surgery were snap-frozen in 
liquid nitrogen and stored at −80°C. The diagnosis of 
lung cancer was confirmed immediately after surgery, 
and the presence of tumor cells was verified by a 
pathologist (GHL) using frozen sections stained with 
hematoxylin and eosin, in accordance with the World 
Health Organization guidelines [22]. The tumor stage 
was assigned according to the American Joint Committee 
for Cancer criteria [23]. Background tissues were 
confirmed to be free of tumor deposits. The follow-up 
time was up to 60 months. All human specimens and 
data were obtained according to a protocol reviewed and 
approved by the local ethical committee, and all patients 
signed an informed consent form. Detailed demographic 
information for all of the patients involved in this study 
is shown in Supplementary Table 1.
RGMB expression analysis by real-time qPCR 
and immunochemical staining
Real-time qPCR was performed using a StepOne 
Plus real-time PCR system (Applied Biosystems, Foster 
City, CA, USA). Briefly, RNA was isolated using the 
TRI Reagent from Sigma (USA) according to the 
manufacturer’s instructions. RNA (0.5 μg) was reverse 
transcribed into cDNA using the iScript™ cDNA Synthesis 
kit (Bio-Rad Life Science, USA). The qPCR assay was 
based on Amplifluor technology. The following primers 
were designed using the Beacon Designer software and 
included a Z sequence: RGMB- forward, 5′-GGCCT 
GGCCACTCATAGATA-3′, reverse,5′-ACTGAACCTG
ACCGTACATCATCTGTCACAGCTTGGTA-3′;GAP 
DH- forward, 5′-AAGGTCATCCATGACAACTT-3′, 
reverse, 5′-ACTGAACCTGACCGTACAGCCATCCAC 
AGTCTTCTG-3′. The qPCR assay was performed with an 
ABI Prism 7900 System (Applied Biosystems) using the 
Absolute Q-PCR ROX Mix (Thermo Fisher Scientific, 
Waltham, MA, USA). The transcript copy number was 
calculated based on an internal standard, GAPDH, 
according to a previously reported method [24]. All of the 
assays were performed in triplicate. RGMB expression 
levels were dichotomized according to the median values. 
The tissue blocks were cut into 5-μm sections and processed 
for IHC in accordance with a previously described protocol 
[15].
Statistical analysis
Progression-free survival (PFS) was defined as the 
minimum interval from the date of diagnosis to the date 
of tumor recurrence, progression, occurrence of a second 
malignancy, death, or the last follow-up. OS was defined 
as the interval from the date of diagnosis to the date of 
death or the last follow-up. Living patients with local 
recurrence or metastasis were considered to be ‘in disease 
survival’. Correlations between RGMB levels and other 
demographical and clinical features were assessed using 
Mann-Whitney rank sum and Kruskal-Wallis one-way 
analysis of variance tests. 
Patients were assigned to two equal-sized groups 
defined by median RGMB expression. Kaplan-Meier 
survival curves and log-rank tests were used to evaluate 
differences in OS and PFS between the two groups. The 
Cox proportional hazards model was used to estimate 
hazard ratios (HRs) and 95% CIs for RGMB levels 
with consideration of other demographic and clinical 
parameters. The survival analyses were performed using 
the SPSS statistical software (Version 11; SPSS, Chicago, 
IL, USA). All of the statistical tests were two-sided, and 
P  < 0.05 was considered statistically significant.
Cell lines, antibodies, and reagents
Human lung adenocarcinoma cell lines A-549 and 
H1299 were obtained from the American Type Culture 
Collection (Manassas, VA, USA). Antibodies against the 
following proteins were used: GAPDH, RGMB, Smad-1/5/8, 
Smad-2/3, JNK, ERK1/2 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), P-Smad-1/5/8, P-Smad-3, P-JNK, and 
P-ERK1/2 (Cell Signaling Technology, Danvers, MA, USA).
Functional studies
For wound healing assays, cells were seeded at a 
density of 1 × 106 cells/well into 6-well plates and then pre-
incubated for 24 h before a wound was created in the cell 
monolayer using a plastic tip. The cells were then grown in 
culture medium supplemented with 1% fetal bovine serum. 
The migration of the cells was tracked and recorded for 
24 h using a microscope (Leica DFC450). Cell migration 
was determined by measuring distances between parallel 
lines indicating the initial sites and migratory sites. The 
procedure was repeated three times. Cell invasion assays 
were performed using modified Boyden chambers (8 µm) 
with polycarbonate membranes (Corning, Corning, NY, 
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USA) coated with 500 µg/mL Matrigel (BD Biosciences, 
San Jose, CA, USA). Cells (20,000) were added to transwell 
inserts on top of the artificial basement membranes. The 
rate of cell growth was measured using a MTS proliferation 
assay (Cell Titer 96 Aqueous One Solution Cell Proliferation 
Assay; Promega, Madison, WI, USA), which was performed 
according to the manufacturer’s instructions.
Electric cell substrate impedance sensing (ECIS) 
assay
An ECIS Z model (Applied Biophysics Inc., Troy, NY, 
USA) was used to analyze migration in a wound model [25] 
in which 8W10E arrays were used. Each of the eight wells 
contained 10 circular 250-μm diameter active electrodes 
connected in parallel on a common gold pad. Each well had a 
substrate area of 0.8 cm2 and a maximum volume of 600 μL. 
In a confluent cell layer, an average of approximately 
500–1,000 cells were measured by the electrodes.
Following the treatment of the array surface with 
a cysteine solution (10 mM), the arrays were incubated 
in serum-free medium for 1 h. The same number of 
cells (80,000/well) was added to each well. When the 
cells reached confluence, the monolayer was electrically 
wounded at 4 V and 30 kHz for 10 seconds. The 
in vitro migration rate was determined using a previously 
described method [19].
Western blot analysis
Protein extraction was performed using RIPA buffer 
[50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 
and 1% sodium deoxycholate (pH 7.4)] supplemented 
with protease inhibitors (phenylmethylsulfonyl fluoride 
and PImix). Protein concentrations were then measured 
using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, 
USA). Protein lysates were resolved via SDS-PAGE and 
then transferred to nitrocellulose membranes (Hybond™-P; 
Amersham Biosciences, Piscataway, NJ, USA), which 
were blocked with TBS containing 0.2% Tween-20 
(TBST) and 5% non-fat dry milk. The membranes were 
incubated with primary antibodies overnight at 4°C. An 
antibody against GAPDH was used as a control for protein 
loading. After washing with TBST, the membranes were 
incubated with a secondary antibody for 1 h at room 
temperature before exposure.
RGMB overexpression and knockdown
Full-length RGMB was synthesized, sequenced, 
and cloned into the pLVX-mCMV-ZsGreen-puro plasmid 
(Biowit Technologies Ltd., China). For overexpression 
experiments, A-549 cells were transfected with 10 µg 
of DNA and 20 µL of Lipofectamine 2000 (Invitrogen, 
Camarillo, CA, USA). The transfected cells were selected 
in complete medium containing puromycin (Invitrogen) 
at 5 μg/mL. To knock down RGMB expression, a shRNA 
that specifically targeted human RGMB (sequence: 
5′-UUAUUAUCUAUGAGUGGCCAGGCCC-3′) was 
purchased from Life Technologies (validation information 
for this shRNA target sequence can also be  obtained from 
Sigma-Aldrich: product number: TRCN0000365323). 
Knockdown was validated using qPCR and Western 
blotting. RNAi expression vectors (pLVX-ShRNA-Puro-
RGMB and the control plasmid pLVX-ShRNA-Puro-
hScramble) were prepared using T4 DNA ligase and the 
EcoRI and MluI restriction endonucleases (New England 
Biolabs, Ipswich, MA, USA) and were isolated using 
a plasmid isolation kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer’s protocol. Lentiviral 
particles were produced via the transient transfection of 
293FT cells (Invitrogen) using the Lipofectamine 2000 
reagent (Invitrogen). For establishment of cell lines with 
the stable knockdown and overexpression of RGMB, 
cells were selected in culture medium containing 5 μg/mL 
puromycin (Invitrogen) after transfection. After 6 weeks 
of selection, resistant colonies stably transfected with 
pLVX-mCMV-ZsGreen-puro-RGMB or pLVX-ShRNA-
Puro-RGMB, or the corresponding controls were pooled.
Animal studies
Animal experiments were performed in the 
Laboratory Animal Center of Guangzhou Institutes of 
Biomedicine and Health (GIBH), and all animal procedures 
were approved by the Animal Welfare Committee of GIBH. 
NOD-scid-IL2Rg-/- (NSI) mice were derived at the GIBH. 
All mice were maintained in Specific pathogen-free cages 
and provided with autoclaved food and water. Protocols 
were approved by the relevant Institutional Animal Care 
and Use Committee. Tumorigenicity was investigated with 
tumor xenograft experiments. Briefly, female 8–10-week-
old NSI mice were injected subcutaneously with 100 
μL of a suspension of RGMB knockdown cells or vector 
control A-549 cells (approximately 1 × 106 cells). Mice 
injected with saline were used as sham controls. Tumor 
formation was monitored for approximately 6 weeks and the 
tumor weight to body weight ratio calculated. Mice with a 
tumor size > 1 cm in any dimension were terminated. Tumor 
size was calculated according to the following formula: 
0.5234 × [long diameter (short diameter)2]. To develop the 
metastatic model, 6–8-week-old female NSI mice were 
transplanted with 1 × 106 A-549 cells through the fundus 
vein under sterile conditions. All of the mice were sacrificed 
by perfusion 6 weeks after the injection. The lungs were 
examined using a two-photon microscope (OLYMPUS, 
FV1200MPE) for the presence of ZsGreen-labeled 
metastatic cells. Specimens were then collected, fixed, and 
sectioned (5 μm) in preparation for hematoxylin and eosin 
staining to determine the site of metastasis. Peripheral 
blood monocytic cells, splenocytes, liver, and bone marrow 
cells were analyzed using an Accuri™ C6 system (BD 
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Biosciences) for the presence of ZsGreen-positive lung 
cancer cells. Tumor loci and tumor cells were counted.
Detection of RGMB CpG island methylation
Genomic DNA was extracted  from four lung 
cancer samples and paired normal adjacent tissues using 
a QIAamp DNA Minikit (Qiagen). Genomic DNA (1 µg) 
was modified with sodium bisulfite using the EZ DNA 
methylation kit (Qiagen), and the DNA methylation 
levels in the clinical samples were determined using 
the MassAR RAY platform (Sequenom, San Diego, CA, 
USA). Briefly, three fragments covering the RGMB 
promoter CpG islands were amplified from the bisulfite-
modified DNA and 61 CpG sites were successfully tested. 
The following primers were designed by the Sequenom 
EpiDesigner:
5′-AGGAAGAGAGTTATTTTTATTTGAGGTT 
GATTGGG-3′ (sense) and 5′- CAGTAATACGACTCACT 
ATAGGGAGAAGGCTCCACAAACATTCCCTTATCT 
ACAAC-3′ (antisense); 5′-AGGAAGAGAGGTTGTAG 
ATAAGGGAATGTTTGTGG-3′ (sense) and 5′-CAGTAA 
TACGACTCACTATAGGGAG AAGGCTTAATCTA 
AAAAACTCCAACC AACCC-3′ (antisense); 5′-AGGA 
AGAGAGGATTTGGGTGT GAGAGAAGAGTTTT-3′ 
(sense) and 5′-CAG TAATACGACTCACTATAGGGA 
GAAGGCTAAAAACCCAA AAAAACCCCTTAAAC-3′ 
(antisense). The methylation data for individual units 
(1–5 CpG sites/ unit) were analyzed using the Typer 4.0 
software from Sequenom.
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